With offices in France (Paris) and in the USA (Princeton, New Jersey), STENTYS became listed on the Paris EuroNext stock exchange (STNT.PA) in October 2010. STENTYS® received CE-Marking for its BMS and DES(P) stents in early 2010 and currently sells its products in more than 8 European countries.
The STENTYS Clinical Program includes both randomised trials and real-life registries, evaluating the STENTYS stent in STEMI with the APPOSITION program, and in bifurcations with the OPEN program. STENTYS has started a 3,000 patient post-market registry in 2012 to examine the real-world use of the STENTYS stent where stent sizing is a concern.

Paris, FR
Size (employees)
28 (est)+4%
Stentys was founded in 2006 and is headquartered in Paris, FR
Report incorrect company information

Stentys Office Locations

Stentys has offices in Princeton and Paris
Paris, FR (HQ)
18 Rue d'Hauteville
Princeton, US
103 Carnegie Center
Show all (2)
Report incorrect company information

Stentys Financials and Metrics

Stentys Financials

Market capitalization (31-Oct-2017)

32.4 m

Closing share price (31-Oct-2017)

Stentys's current market capitalization is €32.4 m.
Show all financial metrics
Report incorrect company information

Stentys Online and Social Media Presence

Embed Graph
Report incorrect company information